Skip to main content

Table 2 Types of bDMARDs administered

From: Clinical remission rate and drug withdrawal status in articular juvenile idiopathic arthritis

Type of bDMARD

Overall

(n = 17 [35%])

RF + PJIA (n = 6 [86%])

RF − PJIA (n = 4 [44%])

OJIA

(n = 7 [22%])

p-value

Tocilizumab

13 (76%)

5 (83%)

3 (75%)

5 (71%)

0.89

Infliximab

1 (6%)

0

0

1 (14%)

0.49

Adalimumab

6 (35%)

3 (50%)

1 (25%)

2 (28%)

0.66

Abatacept

2 (12%)

1 (17%)

1 (25%)

0

0.44

  1. Data are presented as n (%)
  2. bDMARD biological disease-modifying antirheumatic drug, OJIA oligoarticular juvenile idiopathic arthritis, PJIA polyarticular juvenile idiopathic arthritis, RF rheumatoid factor
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096